Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis.
Gurke R, Bendes A, Bowes J, Koehm M, Twyman RM, Barton A, Elewaut D, Goodyear C, Hahnefeld L, Hillenbrand R, Hunter E, Ibberson M, Ioannidis V, Kugler S, Lories RJ, Resch E, Rüping S, Scholich K, Schwenk JM, Waddington JC, Whitfield P, Geisslinger G, FitzGerald O, Behrens F, Pennington SR; HIPPOCRATES Consortium. Gurke R, et al. Among authors: hillenbrand r. Biomedicines. 2022 Sep 24;10(10):2387. doi: 10.3390/biomedicines10102387. Biomedicines. 2022. PMID: 36289648 Free PMC article. Review.
ImmUniverse Consortium: Multi-omics integrative approach in personalized medicine for immune-mediated inflammatory diseases.
Vetrano S, Bouma G, Benschop RJ, Birngruber T, Costanzo A, D'Haens GRAM, Frasca L, Hillenbrand R, Iversen L, Johansen C, Kaser A, Koenen HJPM, Noehammer C, Peyrin-Biroulet L, Raes J, Ricotti L, Rosenstiel P, Satagopam VP, Schreiber S, Vermeire S, Wollenberg A, Weidinger S, Ziemek D, Danese S; ImmUniverse Consortium. Vetrano S, et al. Among authors: hillenbrand r. Front Immunol. 2022 Nov 9;13:1002629. doi: 10.3389/fimmu.2022.1002629. eCollection 2022. Front Immunol. 2022. PMID: 36439150 Free PMC article.
IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
Krueger JG, Wharton KA Jr, Schlitt T, Suprun M, Torene RI, Jiang X, Wang CQ, Fuentes-Duculan J, Hartmann N, Peters T, Koroleva I, Hillenbrand R, Letzkus M, Yu X, Li Y, Glueck A, Hasselberg A, Flannery B, Suárez-Fariñas M, Hueber W. Krueger JG, et al. Among authors: hillenbrand r. J Allergy Clin Immunol. 2019 Sep;144(3):750-763. doi: 10.1016/j.jaci.2019.04.029. Epub 2019 May 24. J Allergy Clin Immunol. 2019. PMID: 31129129 Free article. Clinical Trial.
CARD10 cleavage by MALT1 restricts lung carcinoma growth in vivo.
Israël L, Glück A, Berger M, Coral M, Ceci M, Unterreiner A, Rubert J, Bardet M, Ginster S, Golding-Ochsenbein AM, Martin K, Hoyler T, Calzascia T, Wieczorek G, Hillenbrand R, Ferretti S, Ferrero E, Bornancin F. Israël L, et al. Among authors: hillenbrand r. Oncogenesis. 2021 Apr 6;10(4):32. doi: 10.1038/s41389-021-00321-2. Oncogenesis. 2021. PMID: 33824280 Free PMC article.
Corrigendum: Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands.
Probert F, Yeo T, Zhou Y, Sealey M, Arora S, Palace J, Claridge TDW, Hillenbrand R, Oechtering J, Kuhle J, Leppert D, Anthony DC. Probert F, et al. Among authors: hillenbrand r. Front Immunol. 2022 Dec 13;13:1095038. doi: 10.3389/fimmu.2022.1095038. eCollection 2022. Front Immunol. 2022. PMID: 36582251 Free PMC article.
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
Dörner T, Kaul M, Szántó A, Tseng JC, Papas AS, Pylvaenaeinen I, Hanser M, Abdallah N, Grioni A, Santos Da Costa A, Ferrero E, Gergely P, Hillenbrand R, Avrameas A, Cenni B, Siegel RM. Dörner T, et al. Among authors: hillenbrand r. Ann Rheum Dis. 2024 Feb 15;83(3):360-371. doi: 10.1136/ard-2023-224691. Ann Rheum Dis. 2024. PMID: 37932009 Free PMC article. Clinical Trial.
Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M, Staubach P, Bauer A, Brehler R, Gericke J, Kangas M, Ashton-Chess J, Jarvis P, Georgiou P, Canvin J, Hillenbrand R, Erpenbeck VJ, Maurer M. Metz M, et al. Among authors: hillenbrand r. Theranostics. 2017 Mar 6;7(5):1266-1276. doi: 10.7150/thno.18304. eCollection 2017. Theranostics. 2017. PMID: 28435464 Free PMC article. Clinical Trial.
133 results